KBC Group
CLDX icon

KBC Group’s Celldex Therapeutics CLDX Stock Holding History

KBC Group’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$76K Hold
2,411
– – ﹤0.01% 1475
2025
Q4 		$65K Hold
2,411
– – ﹤0.01% 1532
2025
Q3 		$62K Hold
2,411
– – ﹤0.01% 1559
2025
Q2 		$49K Sell
2,411
-1,317
-35% -$25.6K ﹤0.01% 1613
2025
Q1 		$68K Hold
3,728
– – ﹤0.01% 1689
2024
Q4 		$94K Buy
3,728
+1,647
+79% +$44.7K ﹤0.01% 1598
2024
Q3 		$71K Buy
2,081
+495
+31% +$18.9K ﹤0.01% 1508
2024
Q2 		$59K Hold
1,586
– – ﹤0.01% 1517
2024
Q1 		$67K Buy
+1,586
New +$65.1K ﹤0.01% 1356

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

KBC Group's CLDX Position: Q1 2026 in Review

KBC Group held its Celldex Therapeutics (CLDX) position steady in Q1 2026 at 2,411 shares worth $76K. The position accounts for ﹤0.01% of the portfolio, ranked #1475.

KBC Group first reported a position in CLDX in Q1 2024 and has held it in 9 quarters since. The position peaked at $94K in Q4 2024. 228 funds tracked by Wall St. Rank hold CLDX as of Q1 2026.

  • KBC Group held 2,411 shares of Celldex Therapeutics worth $76K as of Q1 2026.
  • KBC Group left its Celldex Therapeutics share count unchanged in Q1 2026.
  • Celldex Therapeutics made up ﹤0.01% of KBC Group's portfolio in Q1 2026, its #1475 holding.
  • KBC Group first reported a position in Celldex Therapeutics in Q1 2024 and has held it in 9 quarters since.
  • KBC Group's Celldex Therapeutics position peaked at $94K in Q4 2024.
  • 228 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2026.

Based on KBC Group's 13F filing for Q1 2026, filed 7 May 2026.